Original from: Illumina

 

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.

 

Second quarter 2026 results

 

- Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth")

- GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%

- GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31

 

"Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications. Based on this performance, we are increasing our revenue and earnings guidance for the year," said Jacob Thaysen, Chief Executive Officer of Illumina. "Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina's ecosystem."

 

Fiscal year 2026 guidance

For fiscal year 2026, we now expect:

 

- Total revenue of $4.60-$4.64 billion, versus prior guidance of $4.52-$4.62 billion

- ROW organic revenue growth greater than 5%, versus prior guidance of 2%-4%

- Non-GAAP operating margin of 23.4%-23.6%, unchanged from prior guidance

- Non-GAAP diluted EPS of $5.30-$5.40, versus prior guidance of $5.15-$5.30 

 

Second quarter results

Capital expenditures for free cash flow purposes were $39 million for Q2 2026. Cash flow provided by operations was $201 million, compared to $234 million in the prior year period. Free cash flow (cash flow provided by operations less capital expenditures) was $162 million for the quarter, compared to $204 million in the prior year period. Depreciation and amortization expense was $70 million for Q2 2026. At the close of the quarter, the company held $1.17 billion in cash, cash equivalents and short-term investments.

 

Source: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026